PROC - Procaps Group Debt to Book Capitalization Ratio

Graphic logo of Procaps Group (PROC)

Macroeconomic volatility in Latin America and currency swings are putting pressure on the business of Procaps Group S.A. (PROC). The current debt-to-equity ratio demonstrates financial stability, where the level of 0.00 represents the current value. This correlates with expansion in the US and plant optimization, as well as the company's status as a reliable global partner for softgel capsule production with strict quality control.

PROC (Procaps Group Corp) Debt to Book Value history from 07/04/2022 to 02/16/2025
Core merchandise of Procaps Group SA

Investors use this ratio to assess financial stability and the extent of the business's dependence on external borrowings. The metric is calculated as the ratio of total debt to the sum of equity and liabilities. The trend of the financial debt-to-balance sheet capital ratio on GURU.Markets visualizes the credit load risk. For Procaps Group S.A. (PROC), this is critical when implementing its global expansion strategy. Monitoring this parameter allows for an assessment of the efficiency of capital management by the Miski family.

Competitors of Procaps Group S.A.

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio TNXP (tonixpharma.com)|China SXT Pharmaceuticals, Inc. (SXTC) - Debt to Book Capitalization Ratio|Eupraxia Pharmaceuticals, Inc. - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio BioHarvest (BHST)|EXOZ: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ORMP|Entera Bio (ENTX) - Debts to Book Value|Debts to Book Capitalization HYFT|Debt to Book Value ABVC BioPharma Inc.|Debts to Book Capitalization CPIX|Debts to Book Capitalization QNTM (Quantum BioPharma Corp)|FibroGen, Inc. (FGEN) - Debt to Book Capitalization Ratio|telomirpharma.com - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio RANI (Rani Therapeutics Inc)|Synergy CHC Corp (SNYR) - Debts to Net Assets|Debt to Book Value rallybio.com RLYB|Lexaria Bioscience Corp. (LEXX) - Debt to Net Assets Ratio|Pulmatrix, Inc. - Debts to Book Capitalization|Debt to Net Assets PTHL|Aptorum Group Limited (APM) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio LYRA (Lyra Therapeutics Inc.)|IBO: Debt to Book Capitalization Ratio|TNFA - Debts to Book Value|cbdMD Corp - Debt to Book Value|PRFX: Debts to Book Capitalization|Debt to Book Capitalization Ratio altamiratherapeutics.com (CYTO)|Debts to Book Capitalization Ratio Lipella Pharmaceuticals Inc|OPTN - Debt to Book Value|Debt to Net Assets Ratio PIRS|PTPI (Petros Pharmaceuticals) - Debt to Book Capitalization Ratio|Debts to Net Assets qlsyy.net QLI|Debt to Book Value SLRN|Debts to Net Assets TFF Pharmaceuticals Inc. TFFP